Dual antiplatelet therapy to inhibit Atherosclerosis and Myocardial injury in patients with Necrotic high-risk coronary plaque Disease Cardiovascular disease is the commonest cause of premature death in the United Kingdom and accounts for thirty percent of all deaths among men and twenty two percent among women. The single largest cause of death is acute myocardial infarction (a heart attack). Heart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely explain the development of narrowing within the heart arteries which can subsequently produce symptoms of angina (chest pain). Previous research has shown a specialised scanner known as a PET (positron emission tomography) scanner can identify these recently ruptured plaques in patients without symptoms of a heart attack and these patients also have changes on a blood test (troponin) which suggest that they are at higher risk of having a heart attack in the future. The aim of this study is to identify these patients using the PET scan and to determine if the markers of increased heart attack risk can be reduced by the use of a blood thinning medication (ticagrelor) which is already a well recognised treatment for people who have suffered a recent heart attack. Image Chief Investigator: Professor David Newby Number and location of participating sites (by region/ country): UK Single Centre at Edinburgh Royal Infirmary EudraCT number: 2014-000952-26 Clinical Trials.gov number is NCT02110303 Funder: Wellcome Trust and AstraZeneca Start and End date of grant award: Wellcome Trust Start Date: Jan 2015, End Date: December 2019 The AstraZeneca Grant Award December 2014-November 2017 Current Status: Now published – DOI: 10.1016/j.jcmg.2019.05.023 Trial Unblinding Information: In circumstances where unblinding is necessary please refer to the protocol and follow instructions provided. Contact details are provided below. UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document. Document ECTU DIAMOND GDPR privacy statement (460.68 KB / PDF) Contact details: Sponsor NHS Lothian and University of Edinburgh - ACCORD Chief Investigator: Professor David Newby, Centre of Cardiovascular Science, Chancellor’s Building, 51 Little France Crescent, Edinburgh EH16 4SB. Principal Investigator: Dr Phillip Adamson Trial Manager: Dr Laura Forsyth ECTU Involvement: Trial management, Statistics, Database and randomisation service (UKCRC) This article was published on 2024-09-24
